Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study
An erratum to this article was published (Pituitary, Apr 2024 ↗)
Authors' conclusion
ICDs with a broad range of psychiatric symptoms are common in individuals with DA-treated prolactinoma and NFPAs. Endocrinologists should be aware of this potential side effect, particularly in patients with a personal history of psychiatric disorder.
Study context
- Population
- Patients with DA-treated prolactinoma and non-function pituitary adenomas (NFPAs) followed in tertiary referral centers
- Participants
- 200 patients
- Outcome
- Prevalence of DA-induced impulse control disorders (ICDs), assessed by modified ICD questionnaires
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
At least one ICD
At least one ICD
52%
Compulsive shopping
28.5%
Punding
24.5%
Hypersexuality
24.5%
Observational data: associations, not effects.
Further findings
Risk factors for ICD (multivariable logistic regression)
| aOR (95% CI) | P value | ||
|---|---|---|---|
| Younger age | 0.92 (0.88–0.97) | p 0.001 | |
| Being single | 0.15 (0.03–0.84) | p 0.03 | |
| Positive history of psychiatric illness | 7.67 (1.37–42.97) | p 0.021 | |
| 0.050.21520Adjusted odds ratio (log scale) |
Number of ICD types
- One type of ICD behavior
- 33%
- Two types
- 12%
- Three types
- 7%
Original publication
Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. Published 12 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →